Study of Canakinumab in Patients With Myelofibrosis

Study of Canakinumab in Patients With Myelofibrosis
Conditions:   Primary Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis;   ET-MF;   Post-polycythemia Vera Related Myelofibrosis;   PV-MF
Intervention:   Drug: Canakinumab
Sponsor:   John Mascarenhas

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 22, 2022Comments | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine